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Abstract: Menkes disease (MD) is a rare recessively inherited lethal disorder of copper metabolism. The gene ATP7A 
defective in MD consists of 23 exons and the coding region encompasses 4500 bp. About 300 distinct mutations, represent-
ing all types, have been identiﬁ  ed in ATP7A. However all mutations identiﬁ  ed so far in the exon 2 to exon 7, corresponding 
to 1869 bp of the coding sequence, result in truncated protein products. No missense mutations have been identiﬁ  ed in this 
region. As about 30% of the total number of mutations identiﬁ  ed are located in exon 2 to exon 7, we have designed a protein 
truncation test (PTT) for rapid detecting of mutations in this part of the gene. In order to determine the applicability of the 
test, we analysed RNA obtained from eleven MD patients with known mutations in this region. As a truncated product could 
be identiﬁ  ed in all the included samples, PTT proves to be a useful technique for rapid detection of mutations in the N-terminal 
part of the ATP7A gene. Furthermore as MD is a X-linked disease, normally only affecting boys, the risk of false negative 
results, due to nonsense mediated RNA decay, leading to allelic exclusion, can be left out of account.
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Introduction
The human disorder Menkes disease (MD) is a rare X-linked recessive lethal disorder of copper 
metabolism (Menkes et al. 1962), which is characterised by mental retardation, severe neurological 
degeneration and connective tissue abnormalities (for review see, Kodama and Murata, 1999). The 
disease is caused by mutations in the ATP7A gene, which encodes a Cu-transporting P-type ATPase 
involved in copper efﬂ  ux from cells and in intracellular transport of copper to copper-requiring enzymes 
(for review see, Lutsenko et al. 2007). The ATP7A protein is normally localized to the trans-Golgi 
network, but translocates to the plasma membrane in response to increased copper concentrations. To 
a large extent the clinical features of Menkes disease can be attributed to malfunction of one or more 
copper-requiring enzymes, such as lysyl oxidase, cytochrome C oxidase, or dopamine beta hydroxylase, 
caused by the deﬁ  ciency of ATP7A (Kodama and Murata, 1999).
ATP7A consist of 23 exons, and the ATG translation initiation codon is located in exon 2. To date, 
others and we have identiﬁ  ed a total of more than 300 different mutations in the ATP7A gene in about 400 
unrelated MD patients with the classical severe form or with one of the atypical phenotypes (Tümer et al. 
1997; Tümer et al. 2003; Møller et al. 2005; unpublished results). Methods used to identify the mutations 
include Fluorescent in situ hybridization (FISH), Southern blot analysis, polymerase chain reaction (PCR) 
ampliﬁ  cation of individual exons, Multiplex PCR, Reverse transcription PCR (RT-PCR), Single-strand 
conformational polymorphism (SSCP) and Dideoxyﬁ  ngerprinting (DDFP). The mutations, representing 
all types, are distributed fairly evenly over the entire coding DNA, from exon 2 to exon 23, although the 
various types of gene mutations are not. Deletions, insertions, nonsense and splice site mutations are found 
scattered all over the gene, whereas missense mutations tend to be clustered in conserved domains of the 
ATPase core. To our knowledge, no missense mutations have so far, been observed in the copper-binding 
region of ATP7A encoded by exon 2 to exon 7. Because all the mutations identiﬁ  ed in exon 2 to exon 7, 
lead to premature termination of the Menkes protein, it was tempting to evaluate the efﬁ  ciency of the 
protein truncation test (PTT) for identiﬁ  cation of mutations in this region.
PTT is based on cell-free transcription and translation of RT-PCR ampliﬁ  ed target mRNA. Proteins 
of lower mass than the expected full-length protein represent translation products derived from trunca-
tion frame shift or stop mutations in the analysed gene. As PTT is an RNA-based method, PTT is able 50
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to test several exons in one step instead of inves-
tigation each exon separately.
Materials and Methods
Patients
The clinical ﬁ  ndings of all the patients suggested 
M.D., and the patients were referred to the Kennedy 
Center for molecular diagnosis of MD. The 
identiﬁ  ed mutations in the 11 patients, conﬁ  rming 
the diagnosis, are summarized in Table 1. Three 
normal controls were also included in the test.
Cell culture conditions
The primary ﬁ  broblasts were cultured in a 1:1 
mixture of RPMI 1640 with 20 mM Hepes buffer 
and Nutrient mixture F10 HAM media, supple-
mented with 7.5% Amnio Max C100 supplement, 
4% foetal calf serum, glutamine, penicillin and 
streptomycin. The cells were incubated at 37 °C 
in sealed ﬂ  asks.
Preparation of RNA and cDNA
Total RNA was isolated from 10
4-10
6 cultured 
ﬁ  broblasts using the QIAgen RNeasy Mini Kit 
(QIAgen) and the RNA was eluted in 50 µl elution 
buffer. Single-stranded cDNA was synthesised 
with Superscript II RNAse H
− Reverse Transcrip-
tase (Gibco BRL) using a mixture of random 
hexamer primers (Pharmacia) and 7.5 µl RNA 
solution in a total volume of 20 µl.
Ampliﬁ  cation of RT-PCR fragments 
followed by PTT
The cDNA ampliﬁ  cations of Menkes cDNAs were 
performed as nested PCR reactions. The PCR 
ampliﬁ  cations were done using 5 Units of Taq Plus 
Long (Stratagene) in High Salt buffer in a total 
volume of 40 µl containing 100 nM of each primer 
and 100 µM dNTP. 2 µl of cDNA was used as 
template in the ﬁ  rst PCR reaction whereas 2 µl of 
the ﬁ  rst PCR reaction was used as template in the 
second and ﬁ  nal PCR reaction. The PCR primers 
used in the ﬁ  rst PCR reaction were MNK-41U 
(ccataggatagagaaacc, -41-24 upstream the ATG 
start codon) and MNK-1962L (aagaccgtctccattgtct-
tattt, corresponding to the sequence encoding 
amino acid 654–647), while MNKT7ATG-U 
(taatacgactcactatagggagaccaccatggatccaagtatgggt-
gtgaat, corresponding to the sequence encoding 
amino acid 1–8 position) and MNK-1962L (atcta-
agtgacttgctgaccgatcctt, corresponding to the 
sequence in exon 8, encoding amino acid 642–634) 
were used in the second nested PCR. The 5' primer 
MNKT7ATG-U contains a T7 RNA-polymerase 
promoter sequence and a Kozak sequence in front 
of the ATG start codon. PCR ampliﬁ  cations were 
performed for 40 cycles (94 °C for 30s, 55 °C for 
1 min and 72 °C for 3 min) followed by 7 min at 
72 °C. The products were analysed on 2% agarose 
gel to verify ampliﬁ  cation. For PTT, 4 µl of the 
ampliﬁ  ed PCR product was translated at 30 °C for 
90 min using the TnT
TM T7-coupled reticulocyte 
lysate translation system (Promega, Madison, WI) 
in the presence of 
35S methionine (Amersham 
Table 1
Patient Exon Nucleotide mutation∗ Mutation  type Consequence
93276 3 c.601 C   T nonsense p.R201X
95249 3 c.609delA deletion Frameshift. Stop at codon 222
94295 4 c.869C   A nonsense pS290X
95228 4 c.796_798delTCAinsCC deletion Frameshift. Stop at codon 305
95250 4 c.893_897delCTTTA deletion Frameshift. Stop at codon 313
95200 6 and 7 c.1554-?_1869+?del  Partial gene deletion Frameshift. Stop at codon 519
95206 6 c.1603    _1606delGCTGins 
TATACC
indels Frameshift. Stop at codon 542
95255 6 c.1639C   T nonsense p.R547X
95239 6 c.1642G   T nonsense p.E548X
95230 7 c.1782C   G nonsense p.Y594X
95241 7 c.1752    _1758del TAGTCTC deletion Frameshift. Stop at codon 625
∗Nucleotide numbering of ATP7A cDNA is according to the ATG start codon. ATP7A reference sequence: NM_000052 with numbering 
starting with 1 at the A in the ATG codon.51
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Pharmacia) in a total reaction volume of 25 µl. 
Translation products were separated on a 10% 
SDS-PAGE gel under reducing conditions, fol-
lowed by ﬁ  xing (ﬁ  x-buffer: 10% v/v acetic acid 
and 50% v/v ethanol) and incubation for 30 min 
in Amplify Amersham NAMP 100 (Amersham 
Pharmacia). The gel was dried before exposure to 
Kodak X-Amat AR ﬁ  lm, XAR−5, at −80 °C for at 
least 24 h.
Results
DNA from eleven patients with known mutations 
in the coding region from exon 2 to exon 7, cor-
responding to the encoding sequence c.1-c.1869, 
were chosen to verify the effect of the mutations 
and to demonstrate the efﬁ  ciency of PTT. All muta-
tions identiﬁ  ed so far in this region, including those 
eleven, lead to a premature termination codon.
The effect of the truncation mutations present in 
the eleven MD patients were analysed by PTT. The 
cDNA sequence encoding the N-terminal part of 
ATP7A, corresponding to the segment from basepair 
1 in exon 2 to basepair, 1927 in exon 8 (Genbank 
NM_000052, +1 corresponds to the A of the ATG 
translation initiation codon) was ampliﬁ  ed by RT-
PCR using RNA isolated from cultured ﬁ  broblasts 
as template. The mutations in the eleven tested 
patients were predicted to introduce a termination 
codon after 200, 221, 289, 304, 312, 518, 541, 546, 
547, 593 or 624 amino acids respectively (Table 1). 
The PCR product ampliﬁ  ed from the control RNA 
direct the synthesis of a protein containing 642 
amino acids residues. The mutations were a mixture 
of single nucleotide mutations leading to termination 
codons, insertions or deletion of few basepair as 
well as a large deletion of two exons.
The resulting protein products obtained after in 
vitro translation were analysed by SDS-PAGE 
(Fig. 1). While the size of the peptides in ten of the 
samples were clearly smaller than the size of the 
fully translated run-off product, corresponding to 
642 amino acids, obtained in the control sample, 
the size of the peptide obtained in MNK95241 
(Fig. 1) was barely detectable from the control 
product. However, the pattern was clearly different. 
While two bands were observed in all the control 
samples (C.1; C.2 and C.3) with an apparently 
molecular weight of 66 kDa and 60 kDa respec-
tively, only one band at approximately 63 kDa 
could be observed in MNK95241. The mutation, 
a seven base pair deletion, in MNK95241 is located 
in exon 7 at nucleotide position c.1752–1758. 
Although, this deletion leads to a shift in the read-
ing frame, formation of a premature termination 
codon was not obtained until further 114 nucleo-
tides downstream, close to the position of the 
reverse primer used for PCR ampliﬁ  cation. This 
mutation leads in total to an open reading frame 
encoding 624 amino acids, only 18 amino acids 
shorter than the wild-type fragment. A difference 
of only 18 amino acids is close to the limit of the 
resolving SDS-PAGE system. As a negative con-
trol, a sample containing water instead of a PCR 
product was investigated by PTT. This sample did 
not lead to any radioactive band after SDS-PAGE 
(not shown).
Discussion
Comparison of the predicted length of the indi-
vidual mutated protein products with the migration 
rate of the in vitro translated products revealed a 
perfect correlation (Fig. 1; Table 1). Interestingly, 
the mutation with the large deletion in sample, 
95200, could have been detected by simple aga-
rose gel electrophoresis of the RT-PCR products. 
As few percentages of all mutations in this region 
are large deletions or splice site mutations this 
quick procedure should be used as an initial 
screening.
False-negative results might derive from muta-
tions near the extreme N or C-terminus of the 
protein product. If the mutation is located close to 
the reverse primer sequence there is a risk that the 
mutation will not be detected if the resulting pre-
mature termination codon is located too close to, 
or even beyond the sequence of the reverse primer. 
If the mutation is located in the forward primer- 
binding site the mutation will not be detected as 
long as a PCR product is produced, because the 
wild type primer sequence will be incorporated in 
the resulting PCR product.
In autosomal inherited disorders, where two 
alleles needs to be investigated, PTT can leads to 
false negative results because in some cases, only 
the normal mRNA is analysed due to nonsense 
mediated decay of the truncated transcripts 
(Kahmann et al. 2002). This problem have forced 
scientist to develop more sensitive non-radioactive 
PTT tests (Kahmann et al. 2002). As MD is a 
X-linked recessive disorder, the risk for false 
negative results as a result of allelic exclusion, can 
be left out of account.52
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In our experience PTT turned out to be a 
sensitive and effective method for detection of 
translation termination mutations, including non-
sense mutations, deletions and insertions in the 
N-terminal part of the ATP7A gene.
In addition to the two products of about 66 kDa 
and 60 kDa a third product of approximately 30 kDa 
could be observed in the control sample. The reason 
for the presence of the 60 kDa and the 30 kDa prod-
uct is unknown. As only one product at about 63 kDa 
is seen in sample MNK95241, it seems that the open 
reading frame in the immediate vicinity of c.1752 
in the wild type provokes the formation of a 60 kDa 
truncated product, corresponding to a product ter-
minated immediately after the sequence encoding 
copper binding site number six. The additional band 
of 30 kDa could also be observed in the major part 
of the other samples. The 30 kDa product was only 
absent in the samples MNK93276 and MNK95249, 
the only samples encoding a truncated products 
below 30 kDa. The 30 kDa product could represent 
a degradation product or more likely be the result 
of premature termination of the protein translation, 
taking place after approximately 270 amino acids 
leading to a protein consisting of the two N-terminal 
copper-binding sites. Further experiments might 
disclosure if truncated products composed of two 
respective six copper binding domains are produced 
in vivo and furthermore if they have any biological 
function.
While PTT appears to be an efﬁ  cient and effective 
method to screen for point mutations in the region 
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Figure 1. PTT of RT-PCR fragments spanning exon 2 to exon 7 of the ATP7A gene. M: Molecular-mass-marker proteins. C1, C2, C3: wild-
type proteins obtained from three control samples. P: patients (patient number refers to Table 1).53
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from exon 2 to exon 7 of the ATP7A gene, other 
methods needs to be used for the rest of the exons. 
For this we routinely use sequencing.
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